27639384|t|Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells
27639384|a|Insulin-like growth factor I receptor (IGF-IR) is expressed on breast cancer cells and involves in metastasis, survival, and proliferation. Currently, application of IGF-IR -targeting monoclonal antibodies (mAbs), alone or in combination with other drugs, is a promising strategy for breast cancer therapy. Single-chain fragment variable (scFv) antibodies have been introduced as appropriate tools for tumor-targeting purposes because of their advantages over whole antibodies. In the present study, we employed a naïve phage library and isolated scFvs against a specific epitope from extracellular domain of IGF-IR by panning process. The selected scFvs were further characterized using polyclonal and monoclonal phage ELISA, soluble monoclonal ELISA, and colony PCR and sequencing. Antiproliferative and apoptotic effects of selected scFv antibodies on breast cancer cell lines were also evaluated by MTT and Annexin V/PI assays. The results of ELISA indicated specific reactions of the isolated scFvs against the IGF-IR peptide, and analyses of PCR product and sequencing confirmed the presence of full length VH and Vκ inserts. Treatment of MCF7 and SKBR3 cells with anti-IGF-IR scFv led to a significant growth inhibition. The results also showed that scFv treatment significantly augmented trastuzumab growth inhibitory effects on SKBR3 cells. The percentage of the apoptotic MCF7 and SKBR3 cells after 24-h treatment with scFv was 39 and 30.70 %, respectively. Twenty-four-hour treatment with scFv in combination with trastuzumab resulted in 44.75 % apoptosis of SKBR3 cells. Taken together, our results demonstrate that the targeting of IGF-IR by scFv can be an effective strategy in the treatment of breast cancer and provide further evidence for effectiveness of dual targeting of HER2 and IGF-IR in breast cancer therapy.
27639384	0	17	Antiproliferative	T033	C0243095
27639384	22	31	apoptotic	T043	C0162638
27639384	54	118	anti-insulin-like growth factor I receptor single chain antibody	T129	C1883036
27639384	122	141	breast cancer cells	T025	C1512505
27639384	142	179	Insulin-like growth factor I receptor	T116,T126,T192	C0140080
27639384	181	187	IGF-IR	T116,T126,T192	C0140080
27639384	192	201	expressed	T045	C0597360
27639384	205	224	breast cancer cells	T025	C1512505
27639384	241	251	metastasis	T046	C4255448
27639384	253	261	survival	T043	C0007620
27639384	267	280	proliferation	T043	C0596290
27639384	308	314	IGF-IR	T116,T126,T192	C0140080
27639384	326	347	monoclonal antibodies	T116,T129	C0003250
27639384	349	353	mAbs	T116,T129	C0003250
27639384	391	396	drugs	T121	C0013227
27639384	403	421	promising strategy	T062	C0035171
27639384	426	447	breast cancer therapy	T061	C1511300
27639384	449	497	Single-chain fragment variable (scFv) antibodies	T129	C1883036
27639384	544	568	tumor-targeting purposes	T033	C0243095
27639384	602	618	whole antibodies	T116,T129	C0003241
27639384	656	675	naïve phage library	T116,T130	C0751719
27639384	680	688	isolated	T169	C0205409
27639384	689	694	scFvs	T129	C1883036
27639384	705	721	specific epitope	T129	C0003316
27639384	727	747	extracellular domain	T087	C1514562
27639384	751	757	IGF-IR	T116,T126,T192	C0140080
27639384	761	776	panning process	T067	C1522240
27639384	791	796	scFvs	T129	C1883036
27639384	830	840	polyclonal	T059	C0014441
27639384	845	867	monoclonal phage ELISA	T059	C0014441
27639384	877	893	monoclonal ELISA	T059	C0014441
27639384	899	909	colony PCR	T063	C0032520
27639384	914	924	sequencing	T169	C1561491
27639384	926	943	Antiproliferative	T033	C0243095
27639384	948	957	apoptotic	T043	C0162638
27639384	978	993	scFv antibodies	T129	C1883036
27639384	997	1021	breast cancer cell lines	T025	C1512505
27639384	1045	1048	MTT	T062	C2986858
27639384	1053	1072	Annexin V/PI assays	T059	C0487602
27639384	1089	1094	ELISA	T059	C0014441
27639384	1131	1139	isolated	T169	C0205409
27639384	1140	1145	scFvs	T129	C1883036
27639384	1158	1172	IGF-IR peptide	T116,T126,T192	C0140080
27639384	1178	1201	analyses of PCR product	T059	C0200931
27639384	1206	1216	sequencing	T169	C1561491
27639384	1231	1239	presence	T033	C0150312
27639384	1255	1272	VH and Vκ inserts	T129	C1883036
27639384	1274	1283	Treatment	T169	C1522326
27639384	1287	1291	MCF7	T025	C0596890
27639384	1296	1307	SKBR3 cells	T025	C1512505
27639384	1313	1329	anti-IGF-IR scFv	T129	C1883036
27639384	1351	1368	growth inhibition	T043	C2244509
27639384	1399	1403	scFv	T129	C1883036
27639384	1404	1413	treatment	T169	C1522326
27639384	1428	1437	augmented	T081	C0205217
27639384	1438	1467	trastuzumab growth inhibitory	T116,T192	C0061917
27639384	1479	1490	SKBR3 cells	T025	C1512505
27639384	1514	1523	apoptotic	T043	C0162638
27639384	1524	1528	MCF7	T025	C0596890
27639384	1533	1544	SKBR3 cells	T025	C1512505
27639384	1556	1565	treatment	T169	C1522326
27639384	1571	1575	scFv	T129	C1883036
27639384	1627	1636	treatment	T169	C1522326
27639384	1642	1646	scFv	T129	C1883036
27639384	1667	1678	trastuzumab	T116,T121,T129	C0728747
27639384	1699	1708	apoptosis	T043	C0162638
27639384	1712	1723	SKBR3 cells	T025	C1512505
27639384	1774	1783	targeting	T044	C1159372
27639384	1787	1793	IGF-IR	T116,T126,T192	C0140080
27639384	1797	1801	scFv	T129	C1883036
27639384	1838	1864	treatment of breast cancer	T061	C1511300
27639384	1920	1929	targeting	T044	C1159372
27639384	1933	1937	HER2	T116,T126,T192	C0069515
27639384	1942	1948	IGF-IR	T116,T126,T192	C0140080
27639384	1952	1973	breast cancer therapy	T061	C1511300